Definition of rheumatoid arthritis flare based on SDAI and CDAI

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ..

OBJECTIVE: To develop and validate definitions for disease flares in rheumatoid arthritis (RA) based on the quantitative Simplified and Clinical Disease Activity Indices (SDAI, CDAI).

METHODS: We analysed RA treatment courses from the Norwegian disease-modifying antirheumatic drug registry (NOR-DMARD) and the Vienna RA cohort. In a receiver operating curve analysis, we determined flare definitions for absolute changes in SDAI and CDAI based on a semiquantitative patient anchor. NOR-DMARD was sampled into an 80%-training cohort for cut point derivation and a 20%-test cohort for internal validation. The definitions were then externally validated in the independent Vienna RA cohort and tested regarding their performance on longitudinal, content, face, and construct validity.

RESULTS: We analysed 4256 treatment courses from NOR-DMARD and 2557 from the Vienna RA cohort. The preliminary definitions for absolute changes in SDAI and CDAI for flare are an increase of 4.7 and 4.5, respectively. The definitions performed well in the test and external validation cohorts, and showed clinical face and construct validity, as flares significantly impact both functional ( ∆ Health Assessment Questionnaire flare vs no-flare +0.43; p<0.001) and structural ( ∆ modified Sharp Score 43% higher after flare; p<0.001) disease outcomes, and reflect consistent worsening across all disease core sets, both patient reported and objective.

CONCLUSION: We here provide novel definitions for flare in RA based on SDAI and CDAI, validated in two large independent real-world cohorts. In times of highly effective medications for RA, and consideration of their tapering, these definitions will be useful for guiding decision making in clinical practice and designing clinical trials.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:83

Enthalten in:

Annals of the rheumatic diseases - 83(2024), 2 vom: 11. Jan., Seite 169-176

Sprache:

Englisch

Beteiligte Personen:

Konzett, Victoria [VerfasserIn]
Kerschbaumer, Andreas [VerfasserIn]
Smolen, Josef S [VerfasserIn]
Kristianslund, Eirik Klami [VerfasserIn]
Provan, Sella A [VerfasserIn]
Kvien, Tore K [VerfasserIn]
Aletaha, Daniel [VerfasserIn]

Links:

Volltext

Themen:

Antirheumatic Agents
Arthritis, Rheumatoid
Epidemiology
Journal Article
Outcome and Process Assessment, Health Care
Recurrence
Therapeutics

Anmerkungen:

Date Completed 15.01.2024

Date Revised 15.01.2024

published: Electronic

Citation Status MEDLINE

doi:

10.1136/ard-2023-224742

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM363830375